← Back to Search

Magnetic Tracer

indocyanine green (ICG) for Colorectal Cancer

Phase 1 & 2

Waitlist Available

Led By Matthew Tillman

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

Study Summary

This trial is testing a new way to map the sentinel lymph node (SLN) using magnetic tracers and indocyanine green (ICG) in patients with colorectal cancer. They are also testing the safety of colonoscopic peritumoral injection of magnetic nanoparticles and ICG.

Eligible Conditions

Colorectal Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To assess the feasibility how the Sentinel Lymph Node (SLN) mapping by using novel magnetic tracers (FerroTrace) and using the indocyanine green (ICG) for colorectal cancer.

Trial Design

1Treatment groups

Experimental Treatment

Group I: FerroTraceTM (magnetic tracer)Experimental Treatment2 Interventions

a special type of fluorescent dye called indocyanine green (ICG) during surgery can help surgeons find the lymph nodes that the cancer is most likely to have spread to in colorectal cancer patients.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

indocyanine green (ICG)

2019

Completed Phase 3

~20

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,966 Previous Clinical Trials

1,804,781 Total Patients Enrolled

Matthew TillmanPrincipal InvestigatorM.D. Anderson Cancer Center

George ChangPrincipal InvestigatorM.D. Anderson Cancer Center

1 Previous Clinical Trials

120 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How extensive is the cohort of participants enrolled in this trial?

"This clinical trial has concluded its recruitment period, having first been posted on March 30th 2023 and last updated on March 10th 2022. For those who are seeking other research opportunities related to colorectal cancer or indocyanine green (ICG), there are currently 1,064 and 30 trials respectively looking for participants."

Answered by AI

Could new participants be enlisted for this medical research?

"The clinicaltrials.gov database indicates that this particular trial is not recruiting participants currently, having first been posted on March 30th 2023 and last updated on March 10th 2022. However, there are 1,094 alternatives available for those seeking to participate in a medical study."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Magnetic Particle-ICG Lymph Node Mapping in Colorectal Cancer

2021. "Magnetic Particle-ICG Lymph Node Mapping in Colorectal Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05092750.